Interaction between BMI and APOE genotype is associated with changes in the plasma long-chain-PUFA response to a fish-oil supplement in healthy participants.

What Was Tested

Researchers studied Fish Oils in this controlled clinical trial publication.

The researchers evaluated the plasma fatty acid (FA) response to a DHA-rich supplement in APOE4 carriers and noncarriers consuming a high-saturated fat diet (HSF diet) and, in addition, evaluated whether being overweight changed this response.

Why It Was Studied

Carriers of the apolipoprotein E ɛ4 (APOE4) allele are lower responders to a docosahexaenoic acid (DHA) supplement than are noncarriers.

This effect could be exacerbated in overweight individuals because DHA metabolism changes according to body mass index (BMI; in kg/m²).

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

This study was part of the SATgenɛ trial.

Fasting plasma samples were collected at the end of each intervention diet.

Plasma total lipids (TLs) were separated into free FAs, neutral lipids (NLs), and phospholipids by using solid-phase extraction, and FA profiles in each lipid class were quantified by using gas chromatography.

What Was Measured

PubMed files the paper under topics including Alleles, Apolipoprotein E4, Body Mass Index, Dietary Supplements, Fatty Acids, Unsaturated, Fish Oils and Genetic Association Studies.

The authors tagged it with the keywords BMI, DHA, apolipoprotein E ɛ4, fatty acid metabolism and lipids.

What This Means in Plain Language

This is a controlled clinical trial of Fish Oils.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (The American journal of clinical nutrition), a journal based in United States.

More context: all human trials.